IP lawyer: Amped-up protection on the cards for recombinant DNA products
Australian patent authorities continue to wrestle with the treatment of gene-related inventions. A new ruling may extend the life of patents covering medicines made with recombinant DNA technology
The deputy president of the Administrative Appeals Tribunal of Australia (AAT) has overturned a decision from the commissioner of patents to find that the term of a patent with Swiss-style claims can be extended when the claims cover the production of a pharmaceutical substance involving recombinant DNA technology (AbbVie Biotechnology Limited v Commissioner of Patents  AATA 682, September 5 2016).
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
One of the advantages of IAM is that it is high quality and yet still accessible and relevant to the non-specialist chief executives and senior managers who don't know what they don't know about IP. It's an important contribution to the upward IP education of senior managers.
International Intellectual Property Strategists Association (INTIPSA)
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.